Cost-effectiveness analysis of sequential therapy of levofloxacin in treating urinary tract infections
Abstract
Objective To analyze the cost-effectiveness drug economic sense of sequential therapy of levofloxacin in treatment of urinary tract infections,in order to provide reference for the rational use of drugs.Methods From January 2010 to January 2013,160 patients with urinary tract infections were randomly divided into experimental group (80 cases) and control group (80 cases).Patients in experimental group were treated by fleroxacin sequential therapy,and patients in control group were treated by fleroxacin intravenous infusion therapy.The effects of the two groups were observed and the economics of the drug costs between the two groups were evaluated.Results In experimental group,36 cases were cured and effective in 35 cases,the total effective rate was 88.75％ ; In control group,34 cases were cured and effective in 36 cases,the total effective rate was 87.50％.Two hundred and two strains of pathogenic bacteria of urine culture were collected from 160 patients,109 strains of experimental group and 93 strains of control group,respectively.After treatment,98 and 85 strains were cleared,respectively,and the clearance rates were 89.91％ and 91.40％,there was no statistically significant difference between the two groups(P ＞ 0.05).The cost and cost-effectiveness ratio of the experimental group were significantly lower than those of the control group(P ＜ 0.05).Conclusions Sequential therapy of levofloxacin in treatment of urinary tract infections has less cost economics,but the effect is…
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.